Posted by Michael Wonder on 12 Apr 2022
Prospective measures to combat rising drug prices in Germany
13 April 2022 - This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
In 2011, Germany introduced a novel price regulation mechanism referred to as the AMNOG process with the intention to stop unregulated pricing by providing a two-step procedure: an evidence assessment and subsequent price negotiation. The AMNOG process is not intended to restrict prescriber volume, but to ensure appropriate drug pricing for products entering Germany. While the prices negotiated at the national level are public, any of the 100+ German public health insurance funds may negotiate additional, confidential discounts with manufacturers.
